UPDATE - UBS Initiates Coverage on Ariad Pharma (ARIA) with a Buy; Ponatinib Can Be A Billion Dollar Drug
Tweet
Share
E-mailGet Alerts ARIA Hot Sheet
Price: $24.82 -0.48%
Rating Summary:
10 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
10 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
UPDATE - UBS initiates coverage on Ariad Pharma (Nasdaq: ARIA) with a Buy. PT $20.
Analyst, Matthew Harrison, said, "We believe Ariad’s lead compound for CML, ponatinib, can be a ~$1B drug in 2nd/3rd line CML alone and is worth $14/share. The potential for long term dosing is a key upside driver underap preciated by the Street (each add’l month of median duration adds ~$0.60/share). Also, we believe modest 1st line market share of ~5% is achievable even with generic Gleevec and add ~$3/share for 1st line. Further, we see AP26113 as an underappreciated asset with key data in 2H12."
"Near-term stance: AP26113 the key driver; ASCO just confirmatory: For the stock, we believe the biggest near-term driver is Phase I/II data from AP26113 in 2H. We believe most already have sig. sales and low risk-adjustments for ponatinib, such that the ASCO data should only confirm the assumed profile and not lead to a major stock move."
To see more ratings on ARIA, Click Here
Analyst, Matthew Harrison, said, "We believe Ariad’s lead compound for CML, ponatinib, can be a ~$1B drug in 2nd/3rd line CML alone and is worth $14/share. The potential for long term dosing is a key upside driver underap preciated by the Street (each add’l month of median duration adds ~$0.60/share). Also, we believe modest 1st line market share of ~5% is achievable even with generic Gleevec and add ~$3/share for 1st line. Further, we see AP26113 as an underappreciated asset with key data in 2H12."
"Near-term stance: AP26113 the key driver; ASCO just confirmatory: For the stock, we believe the biggest near-term driver is Phase I/II data from AP26113 in 2H. We believe most already have sig. sales and low risk-adjustments for ponatinib, such that the ASCO data should only confirm the assumed profile and not lead to a major stock move."
To see more ratings on ARIA, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Starts Urban Company (URBANCO:IN) at Buy
- TD Cowen Resumes IsoEnergy Ltd (ISO:CN) at Buy
- Goldman Sachs Starts State Bank of India (SBIN:IN) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
